Pfizer Inc. $PFE Stock Holdings Increased by Park Avenue Securities LLC

Park Avenue Securities LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 20.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 237,963 shares of the biopharmaceutical company’s stock after buying an additional 41,031 shares during the period. Park Avenue Securities LLC’s holdings in Pfizer were worth $5,925,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Fiduciary Alliance LLC grew its position in shares of Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after buying an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $3,019,000. Money Concepts Capital Corp boosted its position in Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after purchasing an additional 57,188 shares during the period. Vista Investment Partners LLC grew its stake in Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after buying an additional 48,900 shares during the last quarter. Finally, Kepler Cheuvreux Suisse SA acquired a new stake in Pfizer in the third quarter worth $16,613,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 1.6%

PFE stock opened at $26.98 on Friday. The firm’s 50-day moving average is $26.68 and its two-hundred day moving average is $25.61. The company has a market capitalization of $153.41 billion, a price-to-earnings ratio of 19.84 and a beta of 0.47. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same period last year, the firm posted $0.63 earnings per share. The business’s revenue was down 1.2% on a year-over-year basis. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Topline Phase 3 win for TALZENNA (talazoparib) + XTANDI: the TALAPRO-3 study met its primary endpoint, showing a significant delay in radiographic progression-free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a meaningful commercial and clinical win for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Additional oncology progress: a Phase II study of atirmociclib in second‑line metastatic breast cancer hit its primary endpoint, supporting pipeline diversification beyond vaccines and COVID-era revenues. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst interest/upgrade flow: recent analyst upgrades and a bullish HSBC forecast have lent buy‑side support and renewed attention to Pfizer’s valuation and upside potential. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Neutral Sentiment: Pfizer-linked investment activity: Earendil Labs closed a $787M financing that included participation from a biotech development fund associated with Pfizer — a sign of strategic R&D/venture exposure but not an immediate earnings driver. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Market commentary and valuation focus: several recent pieces reassess Pfizer’s valuation and compare it to peers (e.g., Moderna), keeping the stock in investors’ screens but creating mixed sentiment around near‑term upside. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Unsolicited mini‑tender offer: Tutanota LLC filed a conditional mini‑tender to buy up to 1M Pfizer shares at $32 — Pfizer has advised shareholders to reject it. The offer is unlikely to be material but can create short‑term trading noise. Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a report on Monday, March 2nd. Citigroup began coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. UBS Group started coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Finally, HSBC boosted their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.14.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.